EIZO (6737) investor relations material

Executive summary

• Net sales reached ¥81,308 million, up 1.0% year-over-year, driven by healthcare sales recovery in Europe, North America, and China.

• Operating profit declined 36.2% year-over-year to ¥2,365 million, impacted by European economic challenges, higher SG&A expenses, and inventory write-downs.

• Net income attributable to owners surged 76.5% year-over-year to ¥7,323 million, mainly due to extraordinary gains from the sale of investment securities.

• Extraordinary losses included ¥441 million for European restructuring and ¥490 million impairment on European assets, totaling ¥1,206 million.

• Healthcare market sales grew 7.2% year-over-year, offsetting declines in B&P, Amusement, and Creative Work segments.

Financial highlights

• Gross profit margin decreased to 31.9% from 32.5% year-over-year, with gross profit at ¥25,901 million.

• Operating profit margin dropped to 2.9% from 4.6% year-over-year.

• Ordinary profit was ¥3,800 million, down 17.2% year-over-year.

• Profit attributable to owners of parent rose 76.5% year-over-year to ¥7,323 million.

• Cash flows from operating activities dropped to ¥5,566 million, with cash and equivalents at period end of ¥20,352 million.

Outlook and guidance

• FY2027 net sales projected at ¥85,000 million, up 4.5% year-over-year.

• Operating profit forecasted to rise to ¥3,300 million, up 39.5% year-over-year.

• Net income expected to decrease to ¥6,500 million due to lower extraordinary gains.

• Dividend per share for FY2027 planned at ¥115, marking the 14th consecutive annual increase.

• Focus on strategic growth, cost control, and restructuring in Europe, with Healthcare and V&S markets expected to drive growth.